Details

Autor(en) / Beteiligte

• Parng, Chuenlei
• Bolt, Michael
• Pittman, Debra D.
• Caiazzo, Teresa
• Dyleski, Lisa
• Gorovits, Boris
• Webster, Rob

Titel

Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXaI16L in Preclinical Species

Ist Teil von

• The AAPS journal, 2019-04, Vol.21 (3), p.52-52, Article 52

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• This paper presents a systemic investigation of ADA development and ADA impact of a human coagulation factor in nonclinical species during drug development and provides insights into potential implications in human if a similar ADA occurs. FXa I16L -induced ADA response was characterized in monkey, mouse, rat, and dog in different studies, and ADA effects on pharmacokinetic and/or pharmacodynamics of FXa I16L were further examined in ADA-negative and ADA-positive animals. After repeated administrations, FXa I16L elicited a dose and exposure day-dependent ADA response which ranged from no response to a transient or persistent response. Increase in exposure day and increase in dose generally enhanced ADA incidence except for a decrease in ADA incidence was observed in monkeys after repeated high-dose administrations. The observable ADA impact on pharmacokinetics was only found in some ADA+ animals and included decrease in clearance and increase in systemic exposure but no increase in half-life. In addition, no or limited effect on pharmacodynamics by ADA was observed. The earliest ADA response was observed after three exposure days, marked elevation of drug exposure was observed in some animals at log titer > 2.0, and the highest antibody titer excited was about 4 (Log10) in all species. A correlation between ADA induction and accumulative exposure after various repeat treatments in different species was found for FXa I16L . In addition, potential immunogenicity risk and mitigation of ADA in clinics are discussed.